Cargando…

Fosfomycin Susceptibility Testing Using Commercial Agar Dilution Test

The reference standard for fosfomycin antimicrobial susceptibility testing (AST) is agar dilution, but it is laborious and is not routinely used in diagnostic microbiology. In this study, we evaluated the performance of a ready-to-use commercially available agar dilution kit for fosfomycin AST (Liof...

Descripción completa

Detalles Bibliográficos
Autores principales: Croughs, Peter D., Konijnendijk-de Regt, Michelle, Yusuf, Erlangga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045359/
https://www.ncbi.nlm.nih.gov/pubmed/35352940
http://dx.doi.org/10.1128/spectrum.02504-21
_version_ 1784695299297509376
author Croughs, Peter D.
Konijnendijk-de Regt, Michelle
Yusuf, Erlangga
author_facet Croughs, Peter D.
Konijnendijk-de Regt, Michelle
Yusuf, Erlangga
author_sort Croughs, Peter D.
collection PubMed
description The reference standard for fosfomycin antimicrobial susceptibility testing (AST) is agar dilution, but it is laborious and is not routinely used in diagnostic microbiology. In this study, we evaluated the performance of a ready-to-use commercially available agar dilution kit for fosfomycin AST (Liofilchem Diagnostics). We compared this kit with the reference standard agar dilution, performed according to the Clinical & Laboratory Standards Institute (CLSI) in 229 clinical isolates. The isolates were selected to represent both Gram-positive and Gram-negative microorganisms, with various MIC values. It consisted of 43 enterococci (E. faecalis n = 16, E. faecium n = 27), 13 methicillin-resistant S. aureus (MRSA), 118 Enterobacterales (Escherichia coli n = 94, Klebsiella pneumoniae n = 20, and Enterobacter cloacae complex n = 4), 55 Pseudomonas aeruginosa, and three ATCC isolates. Using CLSI breakpoints for enterococci for oral treatment of urinary tract infections, European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints for intravenous dosing for Enterobacterales and Staphylococci, and epidemiological cutoff value for P. aeruginosa, the essential agreement was 87.5%, and 99.6% after discrepancy resolution. There was no very major error, and 1.9% major error before, and 0.9% major error after resolution of discrepancies. The commercial test showed 100% reproducibility. In conclusion, in comparison to the reference standard, the ready-to-use commercially available agar dilution kit for fosfomycin AST showed excellent performance. IMPORTANCE Fosfomycin is increasingly needed to treat infection due to multidrug resistant microorganisms. Yet, the antimicrobial susceptibility test (AST) of fosfomycin is fraught with difficulties or often laborious to perform. An easy-to-use AST method for fosfomycin is thus needed. In this study, we showed that the ready-to-use commercially available agar dilution kit, in comparison to the reference standard, showed excellent performance.
format Online
Article
Text
id pubmed-9045359
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-90453592022-04-28 Fosfomycin Susceptibility Testing Using Commercial Agar Dilution Test Croughs, Peter D. Konijnendijk-de Regt, Michelle Yusuf, Erlangga Microbiol Spectr Research Article The reference standard for fosfomycin antimicrobial susceptibility testing (AST) is agar dilution, but it is laborious and is not routinely used in diagnostic microbiology. In this study, we evaluated the performance of a ready-to-use commercially available agar dilution kit for fosfomycin AST (Liofilchem Diagnostics). We compared this kit with the reference standard agar dilution, performed according to the Clinical & Laboratory Standards Institute (CLSI) in 229 clinical isolates. The isolates were selected to represent both Gram-positive and Gram-negative microorganisms, with various MIC values. It consisted of 43 enterococci (E. faecalis n = 16, E. faecium n = 27), 13 methicillin-resistant S. aureus (MRSA), 118 Enterobacterales (Escherichia coli n = 94, Klebsiella pneumoniae n = 20, and Enterobacter cloacae complex n = 4), 55 Pseudomonas aeruginosa, and three ATCC isolates. Using CLSI breakpoints for enterococci for oral treatment of urinary tract infections, European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints for intravenous dosing for Enterobacterales and Staphylococci, and epidemiological cutoff value for P. aeruginosa, the essential agreement was 87.5%, and 99.6% after discrepancy resolution. There was no very major error, and 1.9% major error before, and 0.9% major error after resolution of discrepancies. The commercial test showed 100% reproducibility. In conclusion, in comparison to the reference standard, the ready-to-use commercially available agar dilution kit for fosfomycin AST showed excellent performance. IMPORTANCE Fosfomycin is increasingly needed to treat infection due to multidrug resistant microorganisms. Yet, the antimicrobial susceptibility test (AST) of fosfomycin is fraught with difficulties or often laborious to perform. An easy-to-use AST method for fosfomycin is thus needed. In this study, we showed that the ready-to-use commercially available agar dilution kit, in comparison to the reference standard, showed excellent performance. American Society for Microbiology 2022-03-30 /pmc/articles/PMC9045359/ /pubmed/35352940 http://dx.doi.org/10.1128/spectrum.02504-21 Text en Copyright © 2022 Croughs et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Croughs, Peter D.
Konijnendijk-de Regt, Michelle
Yusuf, Erlangga
Fosfomycin Susceptibility Testing Using Commercial Agar Dilution Test
title Fosfomycin Susceptibility Testing Using Commercial Agar Dilution Test
title_full Fosfomycin Susceptibility Testing Using Commercial Agar Dilution Test
title_fullStr Fosfomycin Susceptibility Testing Using Commercial Agar Dilution Test
title_full_unstemmed Fosfomycin Susceptibility Testing Using Commercial Agar Dilution Test
title_short Fosfomycin Susceptibility Testing Using Commercial Agar Dilution Test
title_sort fosfomycin susceptibility testing using commercial agar dilution test
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045359/
https://www.ncbi.nlm.nih.gov/pubmed/35352940
http://dx.doi.org/10.1128/spectrum.02504-21
work_keys_str_mv AT croughspeterd fosfomycinsusceptibilitytestingusingcommercialagardilutiontest
AT konijnendijkderegtmichelle fosfomycinsusceptibilitytestingusingcommercialagardilutiontest
AT yusuferlangga fosfomycinsusceptibilitytestingusingcommercialagardilutiontest